文献速递肿瘤 PET/CT放射性药物与辐射防护

用PET和SPECT对DNA损伤反应进行成像

Imaging the DNA damage response with PET and SPECT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-01-05

本文综述了近年来开发用于成像DNA损伤修复蛋白的PET和SPECT放射性示踪剂的工作。DNA损伤反应(DDR)在肿瘤发生和癌症治疗中发挥作用,利用核医学技术无创监测这些修复过程可能有助于更早发现癌症并协助监测对DNA损伤治疗的反应。

要点

  • DNA损伤反应(DDR)可检测多种DNA损伤并启动相应修复过程。
  • 各DNA修复通路会招募、上调或激活核内特定蛋白,这些蛋白可成为分子成像靶点。
  • 开发PET和SPECT放射性示踪剂用于成像DNA损伤修复蛋白是本文综述主题。

核心结论

  • 利用核医学技术无创监测DNA修复过程可能有助于更早发现癌症,也可能协助监测对DNA损伤治疗的反应。

研究设计与样本

  • 本文为综述文章,旨在概述近期开发用于成像DNA损伤修复蛋白的PET和SPECT放射性示踪剂的工作。

主要发现

  • DNA损伤反应(DDR)系列复杂机制能检测各种类型的DNA损伤并刺激相应修复过程。
  • 每种DNA损伤修复通路导致核内特定蛋白的招募、上调或激活,其中一些蛋白可代表有吸引力的分子成像靶点。
  • DDR在肿瘤发生和癌症治疗中已有明确参与。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA integrity is constantly challenged by endogenous and exogenous factors that can alter the DNA sequence, leading to mutagenesis, aberrant transcriptional activity, and cytotoxicity. Left unrepaired, damaged DNA can ultimately lead to the development of cancer. To overcome this threat, a series of complex mechanisms collectively known as the DNA damage response (DDR) are able to detect the various types of DNA damage that can occur and stimulate the appropriate repair process. Each DNA damage repair pathway leads to the recruitment, upregulation, or activation of specific proteins within the nucleus, which, in some cases, can represent attractive targets for molecular imaging. Given the well-established involvement of DDR during tumorigenesis and cancer therapy, the ability to monitor these repair processes non-invasively using nuclear imaging techniques may facilitate the earlier detection of cancer and may also assist in monitoring response to DNA damaging treatment. This review article aims to provide an overview of recent efforts to develop PET and SPECT radiotracers for imaging of DNA damage repair proteins.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Knight JC, Koustoulidou S, Cornelissen B, et al. Imaging the DNA damage response with PET and SPECT. Eur J Nucl Med Mol Imaging. 2017. PMID: 28058462. doi:10.1007/s00259-016-3604-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。